Lumida
/ACHC
⌘K
Acadia Healthcare Company Inc

Acadia Healthcare Company Inc

ACHC
$28.36USD-0.60%-0.17 today

MARKET CAP

2.6B

P/E (TTM)

FWD P/E

DAY RANGE

$28 – $29

52W RANGE

$11
$36

AI Summary

Stalk
Sell NowMedium

ACHC is entrenched in a Stage 4 decline with bearish medium-term bias confirmed by the Bearish Pivot Point. Long-term trend remains bullish above the rising 200-day SMA, but recent repair attempts have failed, shifting bias downward. Short-term execution favors selling now into resistance around the 9-/20-day EMA zone as rallies continue to be rejected.

  • Q1 revenue reached $828.8M, up 7.6% YoY driven by acute inpatient care
  • Generated $124M in free cash flow and reduced debt by $113M
  • Medicaid volume fell below expectations, denting revenue growth
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) is a prominent provider in the behavioral healthcare sector in the United States, offering specialist treatments for mental health and substance use disorders through a network of facilities, including inpatient and outpatient settings. The company plays a crucial role in responding to the rising demand for mental health services amid increasing awareness and regulatory support for behavioral healthcare. Under the current leadership of CEO Debbie Osteen, Acadia is committed to operational excellence, facility expansion, and strategic collaborations to enhance its service offerings.

Bull says

  • Q1 revenue reached $828.8M, up 7.6% YoY driven by acute inpatient care
  • Generated $124M in free cash flow and reduced debt by $113M
  • Plans to add 400–600 new beds in 2026 to boost capacity and revenue
  • Quality initiatives and tech enhancements could drive $200M incremental EBITDA
  • Strong demand amid regulatory support underpins growth
  • High momentum and liquidity factors indicate favorable stock dynamics

Bear says

  • Medicaid volume fell below expectations, denting revenue growth
  • Bad debts and denials worsened in Q1, impacting cash flow
  • Projected startup losses of $60–65M from new facility ramp-ups
  • Regulatory changes may reduce EBITDA by $25–30M
  • Weak profitability and growth factors signal expansion challenges
  • Competition and reimbursement volatility heighten operational risks

Investment themes with ACHC

Health Care Providers -0.37%

UNH · CVS · HCA

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-14-2026neutral

Transcript signals

Bull points

  • We reported solid top-line growth with total revenue of 869.2 million, up 9.2% over the second quarter last year, while adjusted EBITDA was 201.8 million, a 7.5% increase over the same period a year ago.
  • For the full year 2025, we expect gross revenue of approximately $230 million from existing state Medicaid supplemental programs.
  • This approval marks a meaningful step in the broader national movement to invest in behavioral health programs that are vital to expanding access, improving outcomes, and meeting the growing demand for behavioral health services across the country.

Bear points

  • we did observe a deterioration in performance at one facility, which continues to face particularly strong local market pressures, which we are closely monitoring.
  • While demand across the majority of our business remains robust, healthcare is inherently local. and we experience pockets of weakness in volumes in certain acute care markets with higher Medicaid exposure.
  • Medicaid volumes at our acute care hospitals were down slightly on a year-over-year basis in the second quarter,
Read full transcript analysis ›